Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Pearl Plernjit French"'
Autor:
Kazuhiko Nakagawa, Elizabeth Olek, Pearl Plernjit French, Kazuko Sakai, Tomoyuki Otani, Masayuki Takeda, S Michael Rothenberg, Satomi Watanabe, Akihiko Ito, Takeshi Yoshida, Jennifer Kherani, Kazuto Nishio
Publikováno v:
JCO Precision Oncology
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74c7947b1275c4e1e1fa93c733a485c9
http://europepmc.org/articles/PMC8140803
http://europepmc.org/articles/PMC8140803
Autor:
Vivek Subbiah, Manisha H. Shah, S Michael Rothenberg, Sophie Leboulleux, Benjamin Solomon, Edward Y. Zhu, Caroline E. McCoach, Jochen H. Lorch, Xin Huang, Pearl Plernjit French, Lori J. Wirth, Taofeek K. Owonikoko, Eric J. Sherman, Francis P. Worden, Matthew H. Taylor, Jyoti D. Patel, Bruce G. Robinson, Maria E. Cabanillas, Marcia S. Brose, Alexander Drilon
Publikováno v:
Journal of the Endocrine Society
The RET receptor tyrosine kinase proto-oncogene is activated by somatic or germline mutations in a majority of medullary thyroid cancers (MTC). However, treatment of MTC has been challenging due to the lack of effective and tolerable RET-specific the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::012d9909d7a16179711a6e699b0c4b0d
http://europepmc.org/articles/PMC7208240
http://europepmc.org/articles/PMC7208240
Autor:
Scott S. Barker, Eric Nadler, Chuck Wentworth, Thomas Wilson, Pearl Plernjit French, Lisa M. Hess, E. Susan Amirian, Marley Boyd, Kathleen M. Aguilar
Publikováno v:
Sarcoma, Vol 2020 (2020)
Sarcoma
Sarcoma
Introduction. This study was designed to describe demographic and clinical characteristics of patients diagnosed with advanced or metastatic soft tissue sarcoma (STS) and to examine treatment and healthcare resource utilization patterns of this patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f33a68f9d298cf12861b6252d6988ec
https://doaj.org/article/6add2362eadf47a7ba2212cc08fb486e
https://doaj.org/article/6add2362eadf47a7ba2212cc08fb486e
Autor:
Keunchil Park, Geoffrey R. Oxnard, Filippo de Braud, Alexander Drilon, Caroline E. McCoach, Daniel Shao Weng Tan, Pearl Plernjit French, Oliver Gautschi, Benjamin Besse, G. Alonso Casal, Victoria Soldatenkova, Koichi Goto
Publikováno v:
Annals of Oncology. 32:S297
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5a0d0330e0fd2f2a451f859bc7ed76c5
https://doi.org/10.1016/j.annonc.2021.05.570
https://doi.org/10.1016/j.annonc.2021.05.570
Autor:
Nora Drove, Victoria Soldatenkova, Lyudmila Bazhenova, Masayuki Takeda, Caroline E. McCoach, Oliver Gautschi, Todd M. Bauer, N. Peled, Jared Weiss, Alexander Drilon, Pearl Plernjit French, Jyoti D. Patel, Vivek Subbiah, Bhavana Konda, Gerald Steven Falchook
Publikováno v:
Cancer Research. 81:CT011-CT011
Introduction: Selpercatinib, a first-in-class highly selective and potent RET kinase inhibitor, is approved in multiple countries for the treatment of RET fusion-positive lung or thyroid cancers. RET fusions are also implicated in the pathogenesis of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f84809d73526ee0f082db01ae012e093
https://doi.org/10.1158/1538-7445.am2021-ct011
https://doi.org/10.1158/1538-7445.am2021-ct011
Autor:
Vivek Subbiah, Manisha H. Shah, Maria E. Cabanillas, Eric J. Sherman, Antoine Italiano, Lori J. Wirth, Daniela Weiler, Matthias Kroiss, Janessa Laskin, Bruce G. Robinson, Alexander Drilon, Jennifer Wright, Victoria Soldatenkova, Pearl Plernjit French
Publikováno v:
Journal of Clinical Oncology. 39:6074-6074
6074 Background: Selpercatinib is a first-in-class, CNS active, highly selective, and potent RET kinase inhibitor which has demonstrated durable antitumor activity in patients (pts) with RET altered thyroid cancer and is approved in multiple countrie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::172d19eaf1b2c8570882e836eb5b8108
https://doi.org/10.1200/jco.2021.39.15_suppl.6074
https://doi.org/10.1200/jco.2021.39.15_suppl.6074
Autor:
Manisha H. Shah, Victoria Soldatenkova, Eric J. Sherman, Antoine Italiano, Jennifer Wright, Daniela Weiler, Lori J. Wirth, Vivek Subbiah, Pearl Plernjit French, Bruce G. Robinson, Maria E. Cabanillas, Matthias Kroiss, Janessa Laskin, Alexander Drilon
Publikováno v:
Journal of Clinical Oncology. 39:6073-6073
6073 Background: Selpercatinib, is a first-in-class, highly selective, CNS active and potent RET inhibitor approved in multiple countries for treatment of RET-fusion positive lung or thyroid cancers. Reported is an update of efficacy and safety resul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::07fef80bed30e5f67b12a7851e7adb11
https://doi.org/10.1200/jco.2021.39.15_suppl.6073
https://doi.org/10.1200/jco.2021.39.15_suppl.6073
Autor:
Juergen Wolf, Guzman Alonso, Pearl Plernjit French, Victoria Soldatenkova, Keunchil Park, Vivek Subbiah, Benjamin Besse, Daniel Shao-Weng Tan, Alexander Drilon, Aimee K. Lin, Oliver Gautschi, Filippo de Braud, Koichi Goto, Benjamin Solomon
Publikováno v:
Journal of Clinical Oncology. 39:9065-9065
9065 Background: Selpercatinib, a first-in-class highly selective and potent, CNS-active RET kinase inhibitor, is approved in multiple countries for treatment of RET fusion+ lung or thyroid cancers. Here we report an update of efficacy and safety res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dd3a2008696f6320481aeae184bd2b8d
https://doi.org/10.1200/jco.2021.39.15_suppl.9065
https://doi.org/10.1200/jco.2021.39.15_suppl.9065
Autor:
Benjamin Solomon, Keunchil Park, Oliver Gautschi, Vivek Subbiah, Guzman Alonso, Filippo de Braud, Victoria Soldatenkova, Daniel Shao-Weng Tan, Koichi Goto, Juergen Wolf, Pearl Plernjit French, Aimee K. Lin, Benjamin Besse, Alexander Drilon
Publikováno v:
Journal of Clinical Oncology. 39:9032-9032
9032 Background: Selpercatinib, a first-in-class highly selective, potent, CNS-active RET kinase inhibitor, is approved in multiple countries for treatment of RET fusion+ lung or thyroid cancers. Selpercatinib demonstrated durable antitumor activity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8d8a3205ca1466caa1b36dde1a50d222
https://doi.org/10.1200/jco.2021.39.15_suppl.9032
https://doi.org/10.1200/jco.2021.39.15_suppl.9032
Autor:
A. Drilon, D.S.W. Tan, K. Park, F. de Braud, Caroline E. McCoach, Koichi Goto, Victoria Soldatenkova, Geoffrey R. Oxnard, Pearl Plernjit French, Oliver Gautschi, G. Alonso Casal, Benjamin Besse
Publikováno v:
Annals of Oncology. 31:S835
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5102fc6fdf666996d8231065414901a4
https://doi.org/10.1016/j.annonc.2020.08.1604
https://doi.org/10.1016/j.annonc.2020.08.1604